Compare Cronos Group Inc (CRON) vs Levi Strauss & Co. (LEVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cronos Group Inc vs Levi Strauss & Co. — how do they compare? Cronos Group Inc trades at $2.74 (market cap $1.03B), while Levi Strauss & Co. trades at $23.72 (market cap $9.31B). The key difference: Levi Strauss & Co. is far larger — about 9× Cronos Group Inc's market cap, and Levi Strauss & Co. pays a 2.65% dividend while Cronos Group Inc pays none. Which is the better fit depends on your goals.
| CRON | LEVI | |
|---|---|---|
Market Cap | $1.03B | $9.31B |
Sector | Health | Consumer Cyclical |
52-Week High | $3.27 | $24.83 |
52-Week Low | $1.95 | $17.92 |
Enterprise Value | $211.19M | $10.63B |
Dividend Yield | — | 2.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRON trades at $2.75, showing no change recently. The stock has a mixed technical outlook with a neutral overall signal but bullish moving averages. Fundamentally, revenue grew to $146.59M in 2025, but net income was negative at -$9.45M. Recent news highlights strong Q1 2026 revenue growth of 40% and expansion of its Spinach brand portfolio, though the company faces intense cannabis sector competition.
Outlook is cautious with growth potential from international expansion and market share gains, but profitability remains a challenge. Risks include regulatory uncertainty and competitive pressures. Analyst sentiment is mixed with 60% hold ratings. The stock presents a speculative opportunity for investors betting on continued top-line growth and eventual margin improvement.
Levi Strauss (LEVI) trades at $24.19, down 0.49% on the day, with a neutral technical signal and strong fundamentals. The company reported Q2 2026 EPS of $0.28, beating estimates of $0.24, and raised full-year guidance. Revenue grew 7.6% year-over-year to $1.56B, driven by direct-to-consumer strength. Valuation metrics show a P/E of 17.28 and P/S of 1.45, with robust profitability including a 61.72% gross margin and 9.66% net margin.
Outlook remains positive with 83% analyst buy ratings and a $28 consensus price target, implying 16% upside. Risks include tariff pressures and foreign exchange volatility noted in recent earnings. The dividend was increased to $0.16, supporting income investors. Continued execution on digital strategy and product expansion provides growth catalysts amid competitive apparel markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →About Levi Strauss & Co.
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →
